Polymer From Ethylenic Monomers Only Patents (Class 424/78.31)
-
Patent number: 6565839Abstract: A composition containing, at least one film-forming polymer and at least one thermal transition agent which undergoes a change of state at a transition temperature Tt chosen within the range from 25° C. to 80° C., the at least one thermal transition agent being not water soluble in water maintained at a temperature below the transition temperature Tt, the at least one film-forming polymer and the at least one thermal transition agent are present in an amount which is sufficient so that the composition is capable of forming a film, at the temperature of a keratinous material, wherein the film has a water uptake (Rc) for hot water maintained at 40° C. of at least 15%, and a water uptake (Rf) for cold water maintained at 20° C. wherein Rc−Rf≧3%, and wherein the at least one film-forming polymer and the at least one thermal transition agent are the same or different. The invention also relates to a cosmetic care or make-up process for a keratinous material.Type: GrantFiled: June 15, 2001Date of Patent: May 20, 2003Assignee: L'Oreal S.A.Inventors: Valérie de la Poterie, Jean Mondet, Frédéric Auguste
-
Publication number: 20030091531Abstract: Insect and animal control compositions and method in which a polymer and solvent are selected to provide a cross-linked film with matrices of sufficient capacity for trapping and being plated by an active ingredient particularly methyl nonyl ketone and other ingredients such as UV light absorber and fragrance, near transparency to UV light, flexibility, and susceptibility to slow degradation by environmental factors so to release the active ingredient, and the composition sprayed onto an area to be controlled.Type: ApplicationFiled: April 11, 2001Publication date: May 15, 2003Inventor: Lon Kensek
-
Patent number: 6562330Abstract: An insoluble polymer is deposited in a body cavity for instance to embolize a vein or pack an aneurysm, the polymer having pendant zwitterionic groups to improve biocompatibility. The insoluble polymer is preferably formed by an in situ gelling step in which a charged, preferably soluble, polymer having pendant zwitterionic groups is introduced in the form of a composition in which it is soluble and is gelled by being mixed with a counterionically charged soluble polymer (polyelectrolyte), to form a polyion complex. Preferably the or each soluble polymer is formed by polymerizing ethylenically unsatured monomers including a zwitterionic monomer, for instance 2-methacryloyloxyethyl-2′-trimethylammoniumethyl phosphate inner salt, an ionic monomer such as trimethylammonium alkyl(alk)acrylate or a sulphoalkyl(alk)acrylate and optionally a diluent monomer such as an alkyl(alk)acrylate.Type: GrantFiled: May 14, 2001Date of Patent: May 13, 2003Assignee: Biocompatibles LimitedInventors: Peter William Stratford, Jane Louise Court, Andrew Lennard Lewis
-
Publication number: 20030086899Abstract: Disclosed are viscoelastic compositions and methods of their use in treating joints, especially in conjunction with trauma and osteoarthritis.Type: ApplicationFiled: November 13, 2002Publication date: May 8, 2003Inventor: Masoud R. Jafari
-
Publication number: 20030086874Abstract: Disclosed are novel compositions for embolizing blood vessels which are particularly suited for treating vascular lesions via catheter delivery.Type: ApplicationFiled: October 28, 2002Publication date: May 8, 2003Inventors: Thomas J. Whalen, Chinh N. Tran, Noah M. Roth, Richard J. Greff
-
Patent number: 6558659Abstract: Pharmaceutical compositions that have excellent storage stability even though they include a active component that is susceptible to degradation in an acidic environment are disclosed. The stabilized pharmaceutical composition of the invention includes a ring-opened 7-substituted-3,5-dihydroxyheptanoic or a ring-opened 7-substituted-3,5-dihydroxyheptenoic acid, or a pharmaceutically acceptable salt thereof, as an active component and a stabilizing effective amount of at least one amido-group containing polymeric compound or at least one amino-group containing polymeric compound, or combination thereof; wherein the stabilized pharmaceutical composition does not contain a stabilizing effective amount of another stabilizer or a combination of other stabilizers.Type: GrantFiled: April 9, 2001Date of Patent: May 6, 2003Assignee: Teva Pharmaceutical Industries Ltd.Inventors: Michael Fox, Ivo Dorossiev
-
Patent number: 6555599Abstract: Ethylene-propylene diene monomer (EPDM) rubber-containing articles that exhibit highly desirable long-term effective antimicrobial characteristics are provided. Such articles are in either solid or blown (foam or sponge) state (or combinations of both in multilayered forms) that can be utilized in a variety of different applications. As silver-based compounds are deleteriously affected by utilization of standard curing agents and curing accelerators, such as sulfur-based compounds and/or systems, the ability to provide such an effective antimicrobial vulcanized rubber article is rather difficult. However, this invention encompasses the presence of different non-sulfur-based curing systems and agents, such as peroxides, as one example, that permit vulcanization and do not irreversibly bind silver ions thereto, thereby resulting in long-term antimicrobial performance of the ultimate rubber article itself.Type: GrantFiled: March 26, 2001Date of Patent: April 29, 2003Assignee: Milliken & CompanyInventors: John G. Lever, Geoffrey R. Haas, Bhawan Patel
-
Patent number: 6555656Abstract: A prion-physiological structure and associated method of formation. A provided abnormal prion has a transforming power over a normal prion to convert the abnornal prion into defective prion that mimics the abnormal prion. A linker molecule is then bonded to the abnormal prion, wherein a polymer that is covalently attached to the linker molecule facilitates formation of a polymerized abnormal prion that does not have the transforming power over the normal prion.Type: GrantFiled: May 18, 2001Date of Patent: April 29, 2003Assignee: Albany Medical CollegeInventor: Mark D. Scott
-
Publication number: 20030077317Abstract: Methods and compositions are provided for enhancing the bioadhesive properties of polymers used in drug delivery systems. The bioadhesive properties of a base polymer are enhanced by incorporating a short chain polymer with one or more free carboxylic groups into the base polymer to enhance the ability of the base polymer to adhere to a tissue surface such as a mucosal membrane. The short chain polymers can be incorporated within a wide range of base polymers including proteins, polysaccharides and synthetic biocompatible polymers. In one embodiment, short chain polymers can be incorporated within base polymers used to form or coat drug delivery systems, such as microspheres, which contain a drug or diagnostic agent. The short chain polymers can either be solubilized and blended with the base polymer before manufacture or else used as a coating with base polymers over existing systems.Type: ApplicationFiled: May 15, 2002Publication date: April 24, 2003Applicant: Brown University Research FoundationInventors: Camilla A. Santos, Jules S. Jacob, Benjamin A. Hertzog, Gerardo P. Carino, Edith Mathiowitz
-
Patent number: 6551598Abstract: Use of a CHV antigen for the preparation of a vaccine against canine herpesvirosis, which is intended to be administered to gestating bitches as close as possible to whelping, preferably during the final third of gestation, and which produces a high level of anti-CHV antibodies in gestating bitches at the time of whelping, inducing protection in the puppies by transfer of antibodies during suckling. Inactivated anti-CHV vaccine or subunit vaccines, which can be used for vaccinating gestating bitches to protect the puppies by transfer of antibodies.Type: GrantFiled: January 18, 2001Date of Patent: April 22, 2003Assignee: MerialInventor: Hervé Poulet
-
Publication number: 20030072804Abstract: This disclosure relates to compositions comprising an open-celled polymeric foam wherein the compositions are useful for sequestering lipophilic materials present in the gastrointestinal tract, thereby inhibiting the absorption of such lipophilic materials by the body. The disclosure further relates to compositions comprising the open-celled polymeric foam wherein the compositions are useful for ameliorating side effects associated with the use of lipase inhibitors. In a preferred embodiment, this disclosure relates to compositions comprising polymeric foam materials made from high internal phase emulsions, where such foams are useful for sequestering lipophilic materials. Further disclosed are compositions comprising open-celled polymeric foams wherein the compositions are useful for the purpose of sequestering aqueous and/or hydrophilic materials present in the gastrointestinal tract, thereby ameliorating diarrhea.Type: ApplicationFiled: February 26, 2002Publication date: April 17, 2003Applicant: The Procter & Gamble CompanyInventors: Bryn Hird, Ronald James Jandacek
-
Publication number: 20030068296Abstract: Disclosed are methods for treating endoleaks arising from endovascular repair of abdominal aortic aneurysms. The disclosed methods involve the in situ sealing of endoleaks after placement of an endovascular prostheses in the abdominal aorta. Sealing of endoleaks is achieved by injection of either a biocompatible polymer or prepolymer fluid composition into the endoleak which composition in situ solidifies to seal the leak. Preferably, the biocompatible fluid composition comprises a contrast agent to allow the clinician to visualize the sealing process.Type: ApplicationFiled: October 28, 2002Publication date: April 10, 2003Inventors: Charlie Ricci, Bart Dolmatch, Andrew H. Cragg, Richard J. Greff
-
Patent number: 6538026Abstract: A composition comprising of a monomer component comprised of at least one alkyl cyanoacrylate and at least one inhibitor, and a second component comprised of a resultant aggregate structure formed from an alkyl cyanoacrylate monomer, an alkyl esterified fatty acid and an opacificant agent where said composition forms a resultant aggregate structure when said composition contacts an anionic environment. The compositions are useful for filling, occluding, partially filling or partially occluding an unfilled volume or space in a mass in an anionic environment. The composition are also useful for ablating diseased or undesired tissue by cutting off the blood supply to the tissue.Type: GrantFiled: May 23, 2000Date of Patent: March 25, 2003Assignee: Provasis Therapeutics, Inc.Inventors: Robert E. Krall, Charles W. Kerber, Kimberly Knox
-
Patent number: 6537576Abstract: The invention relates to a novel biologically active composition which comprises a biologically active agent composition which comprises a biologically active agent to be released therefrom, said biologically active agent being dissolved and/or dispersed in a supersaturated state within a carrier, which carrier comprises a liquid and/or solid non-crystalline ester and/or polyester matrix, and where the precipitation of said biologically active agent is substantially, or completely, inhibited therein. Said supersaturated states is obtainable by subjecting one or more carrier staring substances(s) to such chemical reaction(s) that an ester and/or polyester matrix is provided, the biologically active agent being added after said chemical reaction(s) has (have) been completed.Type: GrantFiled: January 29, 2001Date of Patent: March 25, 2003Assignee: Bioglan ABInventors: Åke Lindahl, Håkan Hagslätt, Catharina Benediktsson, Richard Bryland
-
Patent number: 6517827Abstract: The present invention relates to a method of inhibiting a toxin in an animal, such as a human, by administering to the animal a therapeutically effective amount of a polymer having a plurality of pendant acid functional groups which are directly attached to the polymer backbone or attached to the polymer backbone by a spacer group. The spacer group can have a length in the range from 0 to about 20 atoms. The toxin is, typically, an exotoxin secreted by a pathogenic microorganism, such as a bacterium.Type: GrantFiled: July 9, 2001Date of Patent: February 11, 2003Assignee: GelTex Pharmaceuticals, Inc.Inventors: Caroline Isabelle Bacon Kurtz, Richard Fitzpatrick
-
Publication number: 20030026822Abstract: The present invention relates to compositions and methods for administering compositions in solutions for killing adult lice and the ova comprising water, PVM/MA Decadiene crosspolymers, propylene glycol, a mixture of cetyl and stearyl alcohols, Ceteareth-20; stearalkonium chloride; benzyl alcohol; hexylene glycol; pentylene glycol, isopropyl alcohol; a mixture of spinosyn A and spinosyn D in a weight ratio of 80:20, BHT; and sodium hydroxide.Type: ApplicationFiled: April 25, 2001Publication date: February 6, 2003Inventors: Herwing Janssen, Kie Ho, Glenn Nystrand, Dexter Williams, C. Scott Lamb
-
Patent number: 6514491Abstract: Poly(ethylene glycol) carbamate derivatives useful as water-soluble pro-drugs are disclosed. These degradable poly(ethylene glycol) carbamate derivatives also have potential applications in controlled hydrolytic degradation of hydrogels. In such degradable hydrogels, drugs may be either trapped in the gel and released by diffusion as the gel degrades, or they may be covalently bound through hydrolyzable carbamate linkages. Hydrolysis of these carbamate linkages releases the amine drug at a controllable rate as the gel degrades.Type: GrantFiled: April 26, 2001Date of Patent: February 4, 2003Assignee: Shearwater CorporationInventors: Michael David Bentley, Xuan Zhao
-
Publication number: 20020198135Abstract: The present invention relates to compositions comprising a biocompatible polymer with phosphorous linkages and a radiosensitizer, and methods of making and using the same.Type: ApplicationFiled: October 12, 2001Publication date: December 26, 2002Inventors: Wenbin Dang, Kam W. Leong, Jeffery A. Williams
-
Patent number: 6497868Abstract: The present invention relates to graft polymer which is characterized in that it is formed by graft polymerization of structural units containing. a quaternary ammonium group represented by general formula (A), (R2 and R3 each represent an alkyl group with from 1 to 3 carbons, and R4 represents an alkyl group with from 3 to 18 carbons. X represents at least one type of ion selected from halogen, sulphate, hydroxide and carboxylic acid ions.), preferably to graft polymer where the structural units containing a quaternary ammonium group represented by general formula (A) are structural units which are represented by general formula (I), (R1 represents at least one species selected from hydrogen, the methyl group and the ethyl group, and n represents an integer in the range 1 to 12. A represents at least one species selected from O, S and NR5. R5 represents hydrogen or an alkyl group with 1 to 12 carbons.Type: GrantFiled: June 30, 1999Date of Patent: December 24, 2002Assignee: Toray Industries, Inc.Inventor: Kazuhiro Tanahashi
-
Publication number: 20020187120Abstract: A method for treating gout and/or reducing serum uric acid levels in a patient is disclosed that includes administering to the patient a therapeutically effective amount of an amine polymer; for example, an aliphatic amine polymer. Examples of polymers useful in the invention are sevelamer hydrogen chloride and colesevelam.Type: ApplicationFiled: April 17, 2002Publication date: December 12, 2002Applicant: GelTex Pharmaceutical, Inc.Inventors: Stephen Randall Holmes-Farley, Steven K. Burke
-
Patent number: 6482392Abstract: An aerosol antimicrobial composition is provided with the following ingredients: a) an anionic polymer or prepolymer; (b) a quaternary ammonium compound, the components (a) and (b) combining to form an antimicrobially effective complex; (c) at least one water-soluble or dispersible organic solvent having a vapor pressure of at least 0.001 mm Hg at 25° C., said at least one organic solvent present in a solubilizing—or dispersion—effective amount; (d) an effective amount of a propellant; and (e) the remainder, water. Further is provided a novel method of decontaminating a surface fouled with microorganisms and a dispenser for said aerosol composition. The novel composition advantageously has both disinfectancy (contact efficacy) and residual antimicrobial efficacy.Type: GrantFiled: June 23, 2000Date of Patent: November 19, 2002Assignee: The Clorox CompanyInventors: Boli Zhou, Maria G. Ochomogo, Elias A. Shaheen, Jessica Y. Chung
-
Publication number: 20020168334Abstract: Stable, viscous, mucoadhesive aqueous compositions which are useful for the prevention and treatment of ulcerative, inflammatory, and/or erosive disorders of mucous membranes and/or the delivery of pharmaceutically active compounds to mucosal surfaces for topical treatment or transfer to the systemic circulation.Type: ApplicationFiled: February 15, 2002Publication date: November 14, 2002Inventors: Jeremy E. Jacob, David P. Nowotnik, Christiane M. Baud
-
Patent number: 6479725Abstract: A method for forming an incision or wound dressing. First, second, and third layers 2-octyl cyanoacrylate adhesive 18, 20, and 22 are applied to a wound or incision site 14, with each layer covering the site 14 and extending to at least about five millimeters from each side of the site 14. After the first, second, and third layers 18, 20, and 22 are allowed to polymerize, a fourth layer 24 of 2-octyl cyanoacrylate adhesive is applied, the fourth layer 24 substantially covering at least one millimeter of the extending edge of the first, second, and third layers 18, 20, and 22. In the case of a high-tension wound or a wound near a joint, the fourth layer 24 extends at least about ten millimeters from each side of the site 14, and a fifth layer 26 of 2-octyl cyanoacrylate adhesive is applied.Type: GrantFiled: June 30, 2000Date of Patent: November 12, 2002Inventor: Lisa M. Brothers
-
Patent number: 6476070Abstract: A composition comprising of a monomer component comprised of at least one alkyl cyanoacrylate and at least one inhibitor, and a second component comprised of a resultant aggregate structure formed from an alkyl cyanoacrylate monomer, an alkyl esterified fatty acid and an opacificant agent where said composition forms a resultant aggregate structure when said composition contacts an anionic environment. The compositions are useful for filling, occluding, partially filling or partially occluding an unfilled volume or space in a mass in an anionic environment. The composition are also useful for ablating diseased or undesired tissue by cutting off the blood supply to the tissue.Type: GrantFiled: February 2, 2000Date of Patent: November 5, 2002Assignee: Provasis Therapeutics Inc.Inventors: Robert E. Krall, Charles W. Kerber, Kimberly Knox
-
Patent number: 6476069Abstract: A composition useful as an embolic agent that selectively creates an embolic blockage in the lumen of a blood vessel, duct, fistula or other like body passageways by combining a monomer component and a second component wherein, said monomer component comprises of a alkyl cyanoacrylate monomer and at least one inhibitor agent; and said second component that functions as an opacificant agent and a polymerization retardant.Type: GrantFiled: January 29, 1999Date of Patent: November 5, 2002Assignee: Provasis Therapeutics Inc.Inventors: Robert E. Krall, Charles W. Kerber, Kimberly Knox
-
Patent number: 6475505Abstract: Concentrates of various classical biocides in a polyester carrier resin when incorporated into a substrate resin, preferably a polyolefin such as polypropylene or polyethylene, provide the substrate polymer which biocidal activity with superior resistance to discoloration (yellowing) than when the biocide is directly incorporated into the substrate polymer as a powder at the same total concentration.Type: GrantFiled: December 20, 1999Date of Patent: November 5, 2002Assignee: Ciba Specialty Chemicals CorporationInventor: Urs Stadler
-
Publication number: 20020150550Abstract: A hydrogel is obtained by combining acrylamide and methylene based-acrylamide, radical initiation and washing with pyrogen-free water or saline solution to give less than 3.5% by weight polyacrylamide, based on the total weight of the hydrogel. The hydrogel may be used as a soft tissue filler endoprosthesis. Also disclosed is a method of filling a soft tissue in a mammal using the endoprosthesis, and a prosthetic device comprising the polyacrylamide hydrogel.Type: ApplicationFiled: August 27, 2001Publication date: October 17, 2002Inventor: Jens Petersen
-
Patent number: 6464970Abstract: An improved method and composition for preventing adhesions during surgery. Tissue surfaces and surgical articles involved in the surgery are coated with a solution of a hydrophilic, polymeric material prior to manipulation of the tissue during surgery. The composition comprises a solution of a polymeric material having a molecular weight of about 500,000 or above having a concentration of from about 0.01 to about 15%, by weight.Type: GrantFiled: March 21, 1994Date of Patent: October 15, 2002Assignee: University of Florida Research Foundation, Inc.Inventors: Eugene P. Goldberg, Yoseph Yaacobi
-
Patent number: 6465001Abstract: Water soluble macromers are modified by addition of free radical polymerizable groups, such as those containing a carbon-carbon double or triple bond, which can be polymerized under mild conditions to encapsulate tissues, cells, or biologically active materials. The polymeric materials are particularly useful as tissue adhesives, coatings for tissue lumens including blood vessels, coatings for cells such as islets of Langerhans, and coatings, plugs, supports or substrates for contact with biological materials such as the body, and as drug delivery devices for biologically active molecules. A medical condition at a localized site is treated by applying a polymerization initiator and then applying a substantially water-soluble, degradable macromer of at least 200 mw and having at least two crosslinkable substituents, and polymerizing the macromer to form a crosslinked polymeric material at the site.Type: GrantFiled: March 3, 1998Date of Patent: October 15, 2002Assignee: Board of Regents, The University of Texas SystemsInventors: Jeffrey A. Hubbell, Chandrashekhar P. Pathak, Amarpreet Sawhney, Neil Desai, Syed Hossainy, Jennifer L. Hill-West
-
Publication number: 20020146386Abstract: The subject invention is a method and material for removing fluid from the intestinal tract of a host and may be useful in treating animals or human patients suffering from fluid overload states. In one embodiment, the subject method involves ingesting an enterically coated non-systemic, non-toxic, non-digestible, water absorbing polymer which absorbs fluid while passing through the intestinal tract. The polymer is excreted in the feces wherein the polymer and absorbed fluid is removed from the body. Preferred polymers include super absorbent acrylic acid polymers, preferably provided in bead form. The polymers may include functional groups for selectively removing blood borne waste products, e.g. urea, from the G.I. tract.Type: ApplicationFiled: November 6, 2001Publication date: October 10, 2002Inventors: Jaime Simon, Alan D. Strickland
-
Patent number: 6461601Abstract: Methods for reducing lipase enzyme activity within a treatment area comprise applying a copolymeric compound having an average molecular weight of at least 400 and a polyalkoxy backbone which comprises at least one branched C1-C30 alkoxy unit and at least one linear C1-C30 alkoxy unit to the treatment area in an amount sufficient to reduce lipase enzyme activity within the treatment area.Type: GrantFiled: September 15, 2000Date of Patent: October 8, 2002Assignee: The Proctor & Gamble CompanyInventors: Barry Stoddart, Emmanuel Narinx
-
Patent number: 6461603Abstract: The present invention provides water-soluble polymer conjugates of the anti-malarial drug, artelinic acid, using water soluble and non-peptidic polymer backbones, such as poly(ethylene glycol). The invention includes conjugates made using mPEG, bifunctional PEG and multi-arm PEG. The invention further includes a method of forming such conjugates and a method of treating malaria using the conjugates.Type: GrantFiled: February 27, 2001Date of Patent: October 8, 2002Assignee: Shearwater CorporationInventors: Michael David Bentley, Xuan Zhao, Jeremy Lloyd Clark
-
Publication number: 20020141969Abstract: A composition comprising of a monomer component comprised of at least one alkyl cyanoacrylate and at least one inhibitor, and a second component comprised of a resultant aggregate structure formed from an alkyl cyanoacrylate monomer, an alkyl esterified fatty acid and an opacificant agent where said composition forms a resultant aggregate structure when said composition contacts an anionic environment. The compositions are useful for filling, occluding, partially filling or partially occluding an unfilled volume or space in a mass in an anionic environment. The composition are also useful for ablating diseased or undesired tissue by cutting off the blood supply to the tissue.Type: ApplicationFiled: February 2, 2000Publication date: October 3, 2002Inventors: Robert E. Krall, Charles W. Kerber, Kimberly Knox
-
Publication number: 20020119116Abstract: Stabilizing an object in the body of a patient involves the injection of a lower critical solution temperature (LCST) material or other flowable material into the body of the patient so that the material contacts the object. The LCST material or other flowable material then forms a gel in the body such that the object is contained at least partially within the gel and thereby stabilized by the gel such that the object can then be easily fragmented within the body and/or retrieved from the body.Type: ApplicationFiled: February 28, 2002Publication date: August 29, 2002Applicant: SciMed Life Systems, Inc.Inventors: Ronald Sahatjian, Arthur Madenjian, Bill Little
-
Patent number: 6436386Abstract: Isolatable, hydroxyapatite-targeting polymeric structures, and biologically active conjugates thereof, are provided. The polymeric structure includes a linear or branched water-soluble and non-peptidic polymer backbone, such as a PEG backbone, having at least two termini, a first terminus being covalently bonded to a hydroxyapatite-targeting moiety, such as a bisphosphonate, and a second terminus covalently bonded to a chemically reactive group, wherein said chemically reactive group is protected or unprotected. Methods of preparing and using hydroxyapatite-targeting polymeric structures, and biologically active conjugates thereof, are also provided.Type: GrantFiled: November 14, 2000Date of Patent: August 20, 2002Assignee: Shearwater CorporationInventors: Michael James Roberts, Antoni Kozlowski
-
Publication number: 20020110536Abstract: The invention relates to a keratotic plug remover comprising, as active ingredients, (A) a polymer having sulfonic or sulfate groups or having salts thereof and (B) a nonionic polymer, and a pack for pores of the skin containing said remover. The use of the pack for pores of the skin permits cleanly keeping the skin and pores of the skin and suppressing the conspicuousness of pores of the skin because the strength of a film formed therefrom is high even under high humidity, and so the film is easy to peel, and keratotic plugs filled in the pores of the skin can be removed with high reliability.Type: ApplicationFiled: November 9, 2001Publication date: August 15, 2002Applicant: KAO CORPORATIONInventors: Takahiro Osumi, Yasuyuki Murase
-
Patent number: 6432418Abstract: A cosmetic or dermatological composition for treating keratinous material, particularly human hair, including a cosmetically or dermatologically acceptable medium containing at least one silicone-grafted polymer with a polysiloxane portion and a portion consisting of a non-silicone organic chain, wherein one of the two portions constitutes the main polymeric chain while the other is grafted onto said main chain, and at least one copolymer with a polysiloxane-polyoxyalkylene linear block as the repetitive units, as well as the uses thereof, are disclosed. Such compositions are particularly suitable for use as rinsable or non-rinsable products for washing and conditioning hair, hair setting or hair styling.Type: GrantFiled: December 30, 1997Date of Patent: August 13, 2002Assignee: L'OrealInventors: Claude Dubief, Christine Dupuis, Daniele Cauwet-Martin
-
Patent number: 6429296Abstract: The present invention provides a complex of human growth hormone and zinc containing human growth hormone and zinc at a molar ratio of about 1:1.6 to about 1:2.4, and a sustained-release preparation which comprises the complex of human growth hormone and zinc and a biodegradable polymer and which has a high entrapment ratio of human growth hormone and exhibits a stable sustained-release suppressing the initial burst.Type: GrantFiled: January 23, 2001Date of Patent: August 6, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Yutaka Yamagata, Masafumi Misaki, Susumu Iwasa
-
Publication number: 20020098150Abstract: A composition useful as an embolic agent that selectively creates an embolic blockage in the lumen of a blood vessel, duct, fistula or other like body passageways by combining a monomer component and a second component wherein, said monomer component comprises of a alkyl cyanoacrylate monomer and at least one inhibitor agent; and said second component that functions as an opacificant agent and a polymerization retardant.Type: ApplicationFiled: January 29, 1999Publication date: July 25, 2002Inventors: ROBERT E. KRALL, CHARLES W. KERBER, KIMBERLY KNOX
-
Patent number: 6419914Abstract: The present invention relates to a method of inhibiting a toxin in an animal, such as a human, by administering to the animal a therapeutically effective amount of a polymer having a plurality of pendant acid functional groups which are directly attached to the polymer backbone or attached to the polymer backbone by a spacer group. The spacer group can have a length in the range from 0 to about 20 atoms. The toxin is, typically, an exotoxin secreted by a pathogenic microorganism, such as a bacterium.Type: GrantFiled: June 11, 2001Date of Patent: July 16, 2002Assignee: GelTex Pharmaceuticals, Inc.Inventors: Caroline Isabelle Bacon Kurtz, Richard Fitzpatrick
-
Patent number: 6413507Abstract: Poly(ethylene glycol) carbamate derivatives useful as water-soluble pro-drugs are disclosed. These degradable poly(ethylene glycol) carbamate derivatives also have potential applications in controlled hydrolytic degradation of hydrogels. In such degradable hydrogels, drugs may be either trapped in the gel and released by diffusion as the gel degrades, or they may be covalently bound through hydrolyzable carbamate linkages. Hydrolysis of these carbamate linkages releases the amine drug at a controllable rate as the gel degrades.Type: GrantFiled: December 23, 1999Date of Patent: July 2, 2002Assignee: Shearwater CorporationInventors: Michael David Bentley, Xuan Zhao
-
Patent number: 6406687Abstract: The invention provides a medical device which comprises a polymer coating. The polymer coating comprises a polymer comprising a polymer backbone and having at least two pendant groups selected from: (a) a polyoxyalkylene ether group, (b) a sulphate group, (c) a sulphonate group, or (d) a sulphamate group, and the polymer is produced by polymerizing monomers having such groups.Type: GrantFiled: November 4, 1998Date of Patent: June 18, 2002Inventors: Ajay Kumar Luthra, Shivpal Singh Sandhu
-
Publication number: 20020064512Abstract: A biocompatible hydrogel comprises a specified content of polyacrylamide and pyrogen-free water. Also disclosed is a method of making the hydrogel and an injectable or implantable endoprosthesis. The hydrogel may also be used to treat a cosmetic or functional defect. Hydrogels specified according to their polyacrylamide content may be used for medical indications, such as an implantable or injectable endoprostheses for mammoplastic reconstruction, implantable or injectable endoprostheses for treating (reflux) oesophagitis, and for body contouring of various body parts.Type: ApplicationFiled: August 27, 2001Publication date: May 30, 2002Inventors: Jens Petersen, Richard Schmidt, Robert Lessel, Jens Eric Sorensen
-
Publication number: 20020062099Abstract: There are provided an adsorbent which can effectively adsorb and remove endogenous cannabinoid in fluid, and a process for removing endogenous cannabinoid in fluid by means of the adsorbent. The adsorbent of endogenous cannabinoid comprising an adsorbent for endogenous cannabinoid comprising a water-insoluble material containing a substance whose solubility parameter &dgr; is at most 12 ((cal/ cm3)½) is obtained. Endogenous cannabinoid in fluid can be effectively adsorbed and removed by contacting the adsorbent of endogenous cannabinoid with fluid containing endogenous cannabinoid.Type: ApplicationFiled: September 25, 2001Publication date: May 23, 2002Applicant: KANEKA CORPORATIONInventors: Fumiyasu Hirai, Tamiji Fujimoto, Hiroshi Sakurai, Shigeo Furuyoshi
-
Publication number: 20020048560Abstract: A keratotic plug remover composition comprising a polymer compound having a salt forming group is disclosed. The composition according to the invention can effectively remove keratotic plugs in the skin pores, so that the conspicuousness of the skin pores is mitigated and clean and healthy skin pores can be maintained. The composition does not hurt the skin.Type: ApplicationFiled: April 30, 2001Publication date: April 25, 2002Applicant: KAO CORPORATIONInventors: Tomohiro Uemura, Masanori Tanahashi, Yoshiyuki Muroi, Yoshinao Kono
-
Publication number: 20020042395Abstract: A method prevents or treats diseases associated with high plasma cholesterol levels. In addition, this method reduces plasma cholesterol levels. The method comprises administering a lipase inhibitor, e.g. orlistat, and a pharmaceutically acceptable bile acid sequestrant.Type: ApplicationFiled: July 25, 2001Publication date: April 11, 2002Inventors: Paul Hadvary, Hans Lengsfeld, Hans Steffen
-
Patent number: 6365146Abstract: Polymers are provided having a structure selected from: R(—O—R1,)x and R(—NH—R1)x wherein R(—O—)x is a polyol moiety and R(—NH—)x is a polyamine moiety, with the x being between 2 and 10, inclusive, and each R1 independently has the structure: wherein a divalent amino acid moiety with R2 being a covalent bond or having from 1 to 8 carbon atoms, and y and z are between 0 and 10, inclusive, provided that y and z are not both 0; is a divalent dicarboxylic acid moiety in which R3 is an alkylene or cyclolkylene group containing from 1 to about 15 carbon atoms substituted with a total of from 1 to about 10 hydroxyl groups, with at least a portion of the hydroxyl groups being acylated with 3 to 24 carbon atom carboxylic acids; and R4 is a poly(alkylene oxide) having the structure: R5—(R6—O—)a—R6—Q— with R5 selected from 1 to 40 carbon atom alkyl groups, —OH—, &mdaType: GrantFiled: April 23, 1999Date of Patent: April 2, 2002Assignee: Rutgers, The State University of New JerseyInventor: Kathryn E. Uhrich
-
Publication number: 20020035142Abstract: Pharmaceutical compositions that have excellent storage stability even though they include a active component that is susceptible to degradation in an acidic environment are disclosed. The stabilized pharmaceutical composition of the invention includes a ring-opened 7-substituted-3,5-dihydroxyheptanoic or a ring-opened 7-substituted-3,5-dihydroxyheptenoic acid, or a pharmaceutically acceptable salt thereof, as an active component and a stabilizing effective amount of at least one amido-group containing polymeric compound or at least one amino-group containing polymeric compound, or combination thereof; wherein the stabilized pharmaceutical composition does not contain a stabilizing effective amount of another stabilizer or a combination of other stabilizers.Type: ApplicationFiled: April 9, 2001Publication date: March 21, 2002Inventors: Michael Fox, Ivo Dorossiev
-
Publication number: 20020028190Abstract: Compositions comprising non-ionic block copolymers are useful for the treatment of autoimmune, inflammatory and proliferative diseases and for reducing graft/implantation rejection. The present invention also relates to methods of treating animals having various autoimmune, inflammatory and proliferative diseases. The present invention also relates to methods of reducing inflammation in an animal comprising administering the compositions of the invention. Also, the present invention relates to methods of reducing autoimmune responses and to methods of reducing graft/implantation rejection comprising administering the compositions of the inventions.Type: ApplicationFiled: May 10, 2001Publication date: March 7, 2002Inventors: Alexander V. Kabanov, Pierre Lemieux, Nadia Guerin, Valery Alakhov
-
Publication number: 20020028220Abstract: A powder-based solid cosmetic composition is provided having a hardness not greater than 75 as measured by an Asker hardness tester type C1L, a porosity of at least 0.4 and an impact resistance of at least 5. A process is also provided for making the powder-based solid cosmetic composition. The composition according to the present invention has excellent skin feel upon use and is not easily broken.Type: ApplicationFiled: July 1, 1999Publication date: March 7, 2002Inventor: AKIO KASHIMOTO